The Clinical Research Support (CRS) office serves as the principal mechanism for Clinical Protocol and Data Management (CPDM) in the Consortium. CRS facilitates the efficient review, approval, and implementation of cancer clinical research throughout the Consortium. CRS services include assistance throughout the protocol life cycle, including protocol development, navigation through review and approval processes, guidance and support in regulatory affairs, training and education, communications, registration of new trials with NCI CTRP, interim staffing, management of cooperative group trials, quality control and assurance, and data and safety management. In 2013, CRS supported 1168 studies, a 29% increase over 2008 and 23% of newly treated patients participated in a therapeutic clinical trial. Since CRS directly manages Consortium training, protocol submission through activation, protocol and consent form control, and provides other critical aspects of clinical trials, its impact to the Consortium's research base is exceptionally strong, and all investigators and study teams conducting clinical research use its services on an everyday basis through the life of a study. CRS staff members are organized into four interactive divisions: Study Implementation Support, Quality and Compliance, Study Support Services, and Data Management and Reporting. Data and safety monitoring encompasses all aspects of data monitoring, verifying data validity and integrity, and ensuring the safety of study participants in clinical trials and clinical trials are monitored based on degree of risk, size and complexity. Together, the Data Safety Monitoring Committee and its Compliance sub-committee ensure that investigator initiated trials are conducted according to all required policies and procedures in order to protect the rights and welfare of human subjects. The Consortium is committed to increasing the participation of minorities and children in clinical research by continuing to build trust and engagement with these populations in our catchment area. New initiatives are underway to minimize barriers to using the health care services of partner institutions, remove eligibility, recruitment or participation barriers, and find ways to encourage participation and retention for populations of all types.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-44
Application #
9617719
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Montgomery, Elizabeth T; Noguchi, Lisa M; Dai, James Y et al. (2018) Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States. AIDS Behav 22:402-411

Showing the most recent 10 out of 1267 publications